Angiogenesis and anti-angiogenesis in neuroblastoma

European Journal of Cancer

Volumn 38, Issue 6, 2002, Pages 750-757

  Ribatti, D ^a   Vacca, A ^a   Nico, B ^a   De Falco, G ^a   Giuseppe Montaldo, P ^b   Ponzoni, M ^b  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b G GASLINI INSTITUTE   (Italy)

Author keywords

Angiogenesis; Angiostatic molecules; Retinoic acid; Tumour progression

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 4 DEDIMETHYLAMINOSANCYCLINE; AE 941; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; BENFLURALIN; CANCER GROWTH FACTOR; CGS 27023A; CILENGITIDE; CISPLATIN; CM 101; COMBRETASTATIN A4; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; EDELFOSINE; ENDOSTATIN; FLAVOPIRIDOL; FUMAGILLOL CHLOROACETYLCARBAMATE; IM 862; INTERLEUKIN 12; LEFLUNOMIDE; MARIMASTAT; MONOCLONAL ANTIBODY LM 609; PACLITAXEL; PRINOMASTAT; SQUALAMINE; TANOMASTAT; THALIDOMIDE; UNINDEXED DRUG; VATALANIB;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; NEUROBLASTOMA; NONHUMAN; ONCOGENE C MYB; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; SOLID TUMOR; TREATMENT OUTCOME; TUMOR CELL; TUMOR DIFFERENTIATION; TUMOR GROWTH;

EID: 0036211599     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00337-9     Document Type: Article

References (71)

1. Mechanisms of angiogenesis
2. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
3. The implications for angiogenesis to the biology and therapy of cancer metastasis
4. Tumor angiogenesis
5. Molecular biology of neuroblastoma
6. Prognostic factors in neuroblastoma
7. A proposed staging for children with neuroblastoma
8. International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma
9. Detection of minimal residual disease in bone marrow during or after therapy as a prognostic marker for high-risk neuroblastoma
10. Biology and genetics of human neuroblastomas
11. Biochemical evidence for a mature phenotype in morphologically poorly differentiate a neuroblastoma with a favourable outcome
12. Age-linked prognostic categorization based on a new histologic grading system of neuroblastomas. A clinicopatholigic study of 211 cases from the Pediatric Oncology Group
13. The international neuroblastoma phatology classification (the Shimada system)
14. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma
15. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas
16. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage
17. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastoma: Correlation with N-myc amplification
18. Cytogenetic findings and prognosis in neuroblastoma with emphasis on marker chromosome 1
19. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma
20. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastoma
21. TRK and RET protooncogene expression in human neuroblastoma specimens: High frequency of TRK expression in non-advanced stages
22. Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis
23. Tumor progression of human neuroblastoma cells tagged with a lacZ marker gene; earlest events at ectopic injection sites
24. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma
25. Human neuroblastoma cells produce extracellular matrix-degrading enzymes, induce endothelial cell proliferation and are angiogenic in vivo
26. Angiogenesis in neuroblastoma: Relationship to survival and other prognostic factors in a cohort of neuroblastoma patients
27. Expression of vascular endothelial growth factor (VEGF) and its receptors in human neuroblastoma
28. Vascular endothelial growth factor expression in human neuroblastoma: Up-regulation by hypoxia
29. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in human neuroblastoma
30. High level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastoma
31. Biology and biochemistry of proteinases in tumor invasion
32. Role of matrix, fibroblasts and type IV collagenases in tumor progression and invasion
33. The role of matrix metalloproteinases and their inhibitors in tumour invasion, metastasis and angiogenesis
34. Immunohistochemical expression of MMP-2, MMP-9, and TIMP-2 in neuroblastoma: Association with tumor progression and clinical outcome
35. Matrix metalloproteinase-2 and-9 are expressed in human neuroblastoma: Contribution of stromal cells to their production and correlation with metastasis
36. Membrane-type matrix metalloprooteinase-1 expression and activation of gelatinase A as prognostic marker in advanced pediatric neuroblastoma
37. Angiogenesis extent and expression of matrix metalloproteinase-2 and-9 correlate with progression in human neuroblastoma
38. The N-myc proto-oncogene: Developmental expression and in vivo site-directed mutagenesis
39. Defects in heart and lung development in compound heterogyzotes for two different targeted mutations at the N-myc locus
40. Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: Evidence for induction of autocrine growth activity
41. Embryonic lethality resulting from disruption of both N-myc alleles in mouse zygotes
42. 3 integrin for angiogenesis
43. v integrins
44. 3 prevents maturation of blood vessels during embryonic neovascularization
45. 3 during angiogenesis
46. Integrins alpha (V) beta 3 and alpha (V) beta 5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide
47. Tumor angiogenesis: Therapeutic implications
48. Inhibitors of angiogenesis in a clinical perspective
49. Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2
50. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth factor
51. Suppression of tumor metastasis by angiogenesis inhibition
52. Potent anti-angiogenic action of AGM-1470: Comparison to the fumagillin parent
53. The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis
54. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth
55. TNP-470 (AGM-1470): Mechanisms of action and early clinical development
56. Clinical trials of antiangiogenic agents
57. Therapeutic potential of the angiogenesis drug TNP-470
58. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents
59. Potentation of cytotoxic cancer therapies by antiangiogenic agents
60. The angiogenesis inhibitor TNP-470 reduces the growth rate of human neuroblastoma in nude rats
61. TNP-470 antiangiogenic therapy for advanced murine neuroblastoma
62. Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with the tumor burden
63. Inhibition of angiogenesis induced chromaffin differentiation and apoptosis in neuroblastoma
64. Inhibition of tumor growth in a human neuroblastoma xenograft model with TNP-470
65. Inhibition of neuroblastoma-induced angiogenesis by fenretinide
66. Antangiogenesis is produced by nontoxic doses of vinblastine
67. Continous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
68. The microtubule-affecting drug paclitaxel has antiangiogenic activity
69. Antiangiogenic potential of camptothecan and topotecan
70. 'Accidental' anti-angiogenic drugs: Anti-oncogene directed signal transduction inhibitors and conventional chemoterapeutic agents as examples
71. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice